• 1. 四川大學(xué)華西醫(yī)院金卡醫(yī)院,成都6100412. 四川大學(xué)公共衛(wèi)生學(xué)院衛(wèi)生經(jīng)濟(jì)學(xué)教研室3. 四川大學(xué)華西醫(yī)院臨床流行病學(xué)教研室4. 四川大學(xué)華西醫(yī)院老年科;

目的 　探討醋柳黃酮治療原發(fā)性高血壓的療效及其成本效果比,為臨床合理用藥提供經(jīng)濟(jì)學(xué)依據(jù).
方法 　普查兩所高校3 971名教職工,將符合納入標(biāo)準(zhǔn)的155名高血壓患者按隨機(jī)數(shù)字表隨機(jī)分為醋柳黃酮組77例和依那普利組78例,進(jìn)行同期非盲法試驗(yàn)6周,觀察治療前后血壓的變化,并計(jì)算治療的總成本,評價(jià)成本-效果.
結(jié)果 　分別以醋柳黃酮和依那普利治療6周并剔除失訪的病例后,兩組患者各有71例完成治療,其血壓(收縮壓/舒張壓)下降幅度分別為12.7±11.6/8.1±5.1 mmHg和15.2±9.7/10.1±7.3 mmHg,總有效率分別為73.24%(52/71)與74.65%(53/71),兩組比較其差異均無統(tǒng)計(jì)學(xué)意義.醋柳黃酮組副作用發(fā)生率為11.27%(8/71),明顯低于依那普利組(29.6%,21/71).醋柳黃酮組治療總成本9 294.6元,每降低1 mmHg血壓(收縮壓/舒張壓)和顯效1例的成本效果比為732/1 147元和179元,低于依那普利組的870/1 310元和250元.敏感性分析提示,當(dāng)依那普利價(jià)格降低至1.8元/5 mg時(shí),醋柳黃酮治療高血壓的成本-效果比仍優(yōu)于依那普利.
結(jié)論 　醋柳黃酮治療原發(fā)性高血壓的效果與依那普利近期療效相當(dāng),副作用低,有經(jīng)濟(jì)學(xué)價(jià)值優(yōu)勢.

引用本文： 廖曉陽,毛正中,王家良,章茂順. 醋柳黃酮治療原發(fā)性高血壓的療效及經(jīng)濟(jì)學(xué)評價(jià). 中國循證醫(yī)學(xué)雜志, 2004, 04(10): 689-692. doi: 復(fù)制

版權(quán)信息： ?四川大學(xué)華西醫(yī)院華西期刊社《中國循證醫(yī)學(xué)雜志》版權(quán)所有，未經(jīng)授權(quán)不得轉(zhuǎn)載、改編

1. ［1］Chinese Guidelines for the management of Hypertension[J]. Chinese Journal of Hypertension, 2000; 8(1): 94.
2. 中國高血壓防治指南[J]. 高血壓雜志, 2000; 8(1): 94.
3. ［2］Drummond MF. Methods for the economic evaluation of health care programs[M]. Oxford: Oxford University Press; 1997. p.157.
4. ［3］Xu DZ. Pharmacoeconomics and its analysis[J]. Chinese J New Drugs Clin Rem, 2000; 19(2): 139.
5. 徐端正. 藥物經(jīng)濟(jì)學(xué)及分析[J]. 中國新藥與臨床雜志, 2000; 19(2): 139.
6. ［4］Alan m, Garber. Advances in cost-effectiveness analysis of health interventions[J]. Handbook of Health Economic, 2000, 1: 270-300.
7. ［5］Chen W, Hu SL. Design and analysis for pharmacoeconomics study[J]. Chinese Journal of Medicinal Guide, 2000; 2 (4): 48-50.
8. 陳文, 胡善聯(lián). 藥物經(jīng)濟(jì)學(xué)研究設(shè)計(jì)與分析方法[J]. 中國醫(yī)藥導(dǎo)刊, 2000; 2 (4): 48～50.
9. ［6］Zhai GX, Kong Y, Cui S. Effect factor for traditional Chinese medicine entering into international market[J]. Chinese Health Economics Magazine, 2003; 22(2): 21-22.
10. 翟光喜, 孔巖, 崔爽. 我國中藥行業(yè)進(jìn)入國際市場影響因素分析[J]. 中國衛(wèi)生經(jīng)濟(jì), 2003; 22(2): 21～22.
11. ［7］Zhu F, Zhang MS, Wang JL, Fu ZY. Inhibitory Effect of total flavones of Hippophae Rhamnoides L. On angiotensin converting enzyme from rabbit[J]. Chinese Journal of clinical Pharmacy, 2000; 9(2): 95-98.
12. 朱福, 章茂順, 王家良, 符宗胤. 醋柳黃酮對家兔血管緊張素轉(zhuǎn)換酶的抑制作用[J]. 中國臨床藥學(xué)雜志, 2000; 9(2): 95～98.
13. ［8］Li JF, Zhang MS, Wang JL, Fu ZY, Liao XY. Effects of Quercetin on intracellular free calcium concentration in cultured rabbit aortic smooth muscle cells[J]. Chinese Journal of Hypertension, 2000; 8(1): 55-57.
14. 李家福, 章茂順, 王家良, 符宗胤, 廖曉陽. 槲皮素對家兔血管平滑肌細(xì)胞胞內(nèi)游離鈣濃度的影響[J]. 高血壓雜志, 2000; 8(1): 55～57.
15. ［9］Gong M, Liao XY, Zhang MS, Wang JL, Fu ZY. The effect of total flavones of Hippophae Rhamnoides L. On intraerythrocytic free calcium concentration and insulin sensitivity of hypertensive patients[J]. Modern Journal of Intergated Chinese Traditional and Western Medicine, 2000; 9(14): 1 303-1 307.
16. 龔銘, 廖曉陽, 章茂順, 王家良, 符宗胤. 醋柳黃酮對高血壓游離鈣及胰島素敏感性的影響[J]. 現(xiàn)代中西醫(yī)結(jié)合雜志, 2000; 9(14): 1 303～1 307.
17. ［10］Mitchell A. Update and evaluation of Australian guidelines perspective[J]. Medical Care, 1996; 34(12): 216.
18. ［11］Menon D. Canada new guidelines for the economics evaluation of pharmaceuticals[J]. Medical Care, 1996; 34(12): 77.
19. ［12］Bombardier C, Maetzel A. Pharmacoeconomic evaluation of new treatment: efficacy versus effectiveness studies. The annals of the rheumatic diseases, 1999; 58(suppl): 182.
  1. 1. ［1］Chinese Guidelines for the management of Hypertension[J]. Chinese Journal of Hypertension, 2000; 8(1): 94.
  2. 2. 中國高血壓防治指南[J]. 高血壓雜志, 2000; 8(1): 94.
  3. 3. ［2］Drummond MF. Methods for the economic evaluation of health care programs[M]. Oxford: Oxford University Press; 1997. p.157.
  4. 4. ［3］Xu DZ. Pharmacoeconomics and its analysis[J]. Chinese J New Drugs Clin Rem, 2000; 19(2): 139.
  5. 5. 徐端正. 藥物經(jīng)濟(jì)學(xué)及分析[J]. 中國新藥與臨床雜志, 2000; 19(2): 139.
  6. 6. ［4］Alan m, Garber. Advances in cost-effectiveness analysis of health interventions[J]. Handbook of Health Economic, 2000, 1: 270-300.
  7. 7. ［5］Chen W, Hu SL. Design and analysis for pharmacoeconomics study[J]. Chinese Journal of Medicinal Guide, 2000; 2 (4): 48-50.
  8. 8. 陳文, 胡善聯(lián). 藥物經(jīng)濟(jì)學(xué)研究設(shè)計(jì)與分析方法[J]. 中國醫(yī)藥導(dǎo)刊, 2000; 2 (4): 48～50.
  9. 9. ［6］Zhai GX, Kong Y, Cui S. Effect factor for traditional Chinese medicine entering into international market[J]. Chinese Health Economics Magazine, 2003; 22(2): 21-22.
  10. 10. 翟光喜, 孔巖, 崔爽. 我國中藥行業(yè)進(jìn)入國際市場影響因素分析[J]. 中國衛(wèi)生經(jīng)濟(jì), 2003; 22(2): 21～22.
  11. 11. ［7］Zhu F, Zhang MS, Wang JL, Fu ZY. Inhibitory Effect of total flavones of Hippophae Rhamnoides L. On angiotensin converting enzyme from rabbit[J]. Chinese Journal of clinical Pharmacy, 2000; 9(2): 95-98.
  12. 12. 朱福, 章茂順, 王家良, 符宗胤. 醋柳黃酮對家兔血管緊張素轉(zhuǎn)換酶的抑制作用[J]. 中國臨床藥學(xué)雜志, 2000; 9(2): 95～98.
  13. 13. ［8］Li JF, Zhang MS, Wang JL, Fu ZY, Liao XY. Effects of Quercetin on intracellular free calcium concentration in cultured rabbit aortic smooth muscle cells[J]. Chinese Journal of Hypertension, 2000; 8(1): 55-57.
  14. 14. 李家福, 章茂順, 王家良, 符宗胤, 廖曉陽. 槲皮素對家兔血管平滑肌細(xì)胞胞內(nèi)游離鈣濃度的影響[J]. 高血壓雜志, 2000; 8(1): 55～57.
  15. 15. ［9］Gong M, Liao XY, Zhang MS, Wang JL, Fu ZY. The effect of total flavones of Hippophae Rhamnoides L. On intraerythrocytic free calcium concentration and insulin sensitivity of hypertensive patients[J]. Modern Journal of Intergated Chinese Traditional and Western Medicine, 2000; 9(14): 1 303-1 307.
  16. 16. 龔銘, 廖曉陽, 章茂順, 王家良, 符宗胤. 醋柳黃酮對高血壓游離鈣及胰島素敏感性的影響[J]. 現(xiàn)代中西醫(yī)結(jié)合雜志, 2000; 9(14): 1 303～1 307.
  17. 17. ［10］Mitchell A. Update and evaluation of Australian guidelines perspective[J]. Medical Care, 1996; 34(12): 216.
  18. 18. ［11］Menon D. Canada new guidelines for the economics evaluation of pharmaceuticals[J]. Medical Care, 1996; 34(12): 77.
  19. 19. ［12］Bombardier C, Maetzel A. Pharmacoeconomic evaluation of new treatment: efficacy versus effectiveness studies. The annals of the rheumatic diseases, 1999; 58(suppl): 182.